J’Onco Mentor Version 9.09 — LUNG PRIMARY

Desktop version. Mobile app coming.

WHAT IS J’ONCO MENTOR?LUNGBREASTHEAD & NECKPROSTATEENDOMETRIUMLIVERADRENAL GLANDKIDNEYTHYROIDBLADDERCOLON & RECTUMMELANOMA OF SKINPANCREASSTOMACHCNSHEMATOPOIETIC DISORDERSTOP CANCER SITESSTORE MANUALRADIATION GUIDESTATE REPORTABILITYICD-10-CM / SECONDARY DXODS RESOURCES

DIAGNOSIS YEAR

Select the diagnosis year first. J’Onco Mentor uses it to establish the standards cycle and to drive year-sensitive routing in this module.

SEER manual—
NAACCR cycle—
Staging context—
Standards statusSelect year
No diagnosis year selected. Year-dependent schema, staging, SSDI, grade, surgery, and manual guidance should not be assumed.

Explore lung anatomy

Select one or more lung lobes on the realistic anatomy diagram. The application will calculate the suggested ICD-O-3 primary site from all selected sites and the documented pattern of involvement. Patient right appears on the left. Realistic regions are approximate educational overlays. Other visible structures are labeled for reference only and are not selectable.

Realistic anterior thoracic view. Select multiple lung lobes independently. Each selected lobe remains highlighted; click that same lobe again to remove it. Other organ names are read-only labels. Patient right appears on the left.

PATIENT RIGHTPATIENT LEFT Select one or more lobes; use the internal view for bronchial regions

Other thoracic anatomy — reference labels only

These structures help orient the lung diagram. They are not clickable and do not change ICD-O-3 coding, tumor laterality, or staging. Labels are approximate; some structures (including the esophagus) are partially obscured in an anterior view.

TracheaHeartEsophagus (posterior)DiaphragmAortic archSuperior vena cavaPulmonary arteriesPulmonary veinsRibsPleuraClavicles

* Posterior structure shown for orientation; its exact position is not visible in this projection. Labels are not intended as a diagnostic anatomical atlas.

Cancer histology and ICD-O-3 coding

Selected lung sites & calculated primary site

Multiple lobes may be selected at the same time. Click a selected lobe again to remove it. The calculated topography is synchronized to the ICD-O-3 Topography / Primary Site field.

This distinction is required when more than one ICD-O lung subsite is selected.
Primary site: —
Select one or more lung sites to calculate a suggested ICD-O-3 topography.
This field stays synchronized with the Primary Site result above. When anatomy is selected, the calculated site controls this field; when no anatomy is selected, you may choose the ICD-O-3 topography manually.
Type a code or name, or use the dropdown below. Both controls stay synchronized.
Selected anatomy sites
No lung lobes selected.
ICD-O-3 Topography

No lung anatomy selected.

ICD-O-3 Morphology / Behavior · Mirrors Cancer Histology

Main bronchi are C34.0; lobar bronchi map to their lung lobes. A segmental bronchus requires documented site-of-origin verification. For a single lesion overlapping two or more lung lobes with no determinable point of origin, use C34.8. Multiple tumors in different lobes of one lung abstracted as a single primary are coded C34.9. Bilateral selections require review under the Lung Solid Tumor Rules and are not collapsed automatically into one C34 code. Laterality remains a separate registry data item.

Associated biomarkers to learn

Lung Multiple Primary Rules & Calculator

Educational decision support based on the current SEER Solid Tumor Rules 2027 update. Use the official manual for final abstraction decisions.

Current rule set: SEER Solid Tumor Rules 2027 · applicable to 2018+ cases, subject to diagnosis-year-specific instructions and effective dates.

1. Confirm a lung primary

Before applying the Lung rules, determine that the tumor represents a primary lung malignancy rather than metastasis from another organ/site.

2. Review number and location of tumors

Document whether there is one tumor or multiple separate/non-contiguous tumors, whether tumors are in the same lung or both lungs, and which lobes or bronchial subsites are involved.

3. Compare histology

Determine whether the tumors have the same histology, different histologies, or different subtypes/variants. Different histologic families can support multiple-primary decisions under the applicable rule.

4. Neuroendocrine vs non-small cell

Pay special attention when one tumor is a neuroendocrine tumor/carcinoma and another is a non-small cell carcinoma. This distinction is specifically addressed by the Lung Solid Tumor Rules.

5. Tumors in both lungs

Bilateral lung tumors are not automatically one primary. Apply the Lung multiple-primary rules using tumor number, histology, timing, and documentation before assigning one topography.

6. Assign histology using the rules

Use the Lung histology rules when more than one histologic term or component is documented. The rules determine which histology to code and when a mixed or more specific code applies.

Guided multiple-primary review

Rule review

Select the tumor pattern, location, and histology relationship to see what should be reviewed in the official Lung Solid Tumor Rules.

Important lung-rule reminders

  • Rule sequencing matters. Stop at the first rule that applies.
  • The rules determine both the number of primaries to abstract and the histology to code.
  • Do not infer one primary solely because tumors are in the same lung or because they share a topography code.
  • Do not infer multiple primaries solely because tumors are bilateral.
  • For histology, do not code “features” or “differentiation” unless a specific ICD-O code exists for that recognized entity.

AJCC STAGING

PATHOLOGIC STAGING CRITERIA — LUNG

Qualifying evidence: Resection specimens (wedge, segmentectomy, lobectomy or pneumonectomy) generally permit pathological assessment of tumor size and extent (pT). Regional lymph node sampling or dissection supports pN; assess nodal stations and laterality under the applicable lung chapter.

pT / pN: Assign only categories supported by the actual pathological evidence and the site-specific AJCC rules. A diagnosis-confirming biopsy does not automatically establish a pathological primary tumor category.

pM: Pathologically proven distant metastasis may support pM1 where the chapter permits; AJCC does not use pM0.

Treatment sequence: Distinguish initial pathological classification (pTNM) from post-neoadjuvant classification (ypTNM). Confirm eligibility, histology, staging chapter and diagnosis-year edition before finalizing.

Source / verification: AJCC · SEER tools and manuals. Educational overview only; verify exact chapter-specific criteria in the licensed AJCC manual.

Lung AJCC staging schema / TNM context

Use the T, N and M controls and site-specific factors below. Verify final AJCC ID, TNM edition and stage group in the approved AJCC/SEER staging system for the diagnosis year.

AJCC Staging Schema

Schema eligibility is based on diagnosis year, primary site, and histology. This educational summary does not replace the AJCC manual or SEER*RSA.

Applicable schemaLungAJCC Version 9
SEER*RSA Schema ID09360Diagnosis years 2025+
Selected primary site—Awaiting selection
Selected histology—Awaiting selection
Primary sites included in the Lung schema

C34.0 Main bronchus · C34.1 Upper lobe · C34.2 Middle lobe · C34.3 Lower lobe · C34.8 Overlapping lesion · C34.9 Lung, NOS

Histology eligibility

Version 9: 8000–8700, 8720–8790, 8972, 8980, 8982.

TNM framework

T = primary tumor extent/size · N = regional lymph nodes · M = distant metastasis. The lymph-node tool provides an educational suggested N category only.

What Changed in AJCC Version 9? — Lung

Key lung-specific differences from AJCC 8th Edition for diagnosis years 2025+.

N2 subdivision

N2a = involvement of a single N2 nodal station. N2b = involvement of multiple N2 nodal stations.

M1c subdivision

M1c1 = multiple extrathoracic metastases within one organ system. M1c2 = multiple extrathoracic metastases in multiple organ systems.

Stage-group changes

Selected T/N combinations moved to different stage groups in Version 9. Examples include T1 N1 M0 → Stage IIA, T1 N2a M0 → Stage IIB, and T3 N2a M0 → Stage IIIA.

T descriptors

No major restructuring of the lung T categories was introduced; the major operational changes are in N, M, and stage grouping.

STAS

Spread Through Air Spaces (STAS) is recognized as a histopathologic descriptor in the Version 9 lung framework, but it is not itself a T, N, or M category.

TNM Stage Group Calculator

The diagnosis year above determines the AJCC edition used for grouping. Clinical and pathologic stage groups are calculated separately. This is an informational staging aid and does not replace the AJCC manual.

Using AJCC Version 9 stage grouping for diagnosis years 2025+.
Clinical TNM
Clinical stage group — Select cT, cN, and cM.
Pathologic TNM
Pathologic stage group — Select pT, pN, and M.

AJCC reminder: pM0 is not a valid category. For a pathologic stage group without distant metastasis, the M component remains clinical (cM0); pathologic M categories apply when distant metastasis is microscopically confirmed.

Schema status: Review the selected year, site, and histology.

Lung Surgery Codes

Surgical Procedure of Primary Site 2023 codes for lung C34.0–C34.9. Select a code to view its registry description.

Surgical Procedure of Primary Site

B000
None; no surgery of primary site; autopsy only.

Stage and Treatment

Select a stage, then choose from the treatment options shown for that stage. This is an educational NCCN-aligned reference, not a patient-specific recommendation.

Select a stage

Select a stage to populate the Treatment dropdown.

Important treatment modifiers
ResectabilityPerformance statusMolecular biomarkers PD-L1ComorbiditiesPrior therapyPatient preference

For NSCLC, biomarker testing can materially change systemic treatment selection, especially in advanced disease. For SCLC, limited-stage and extensive-stage pathways differ substantially.

Guideline context

Built as an educational overview using current NCCN lung cancer guidance, with NCI/ACS stage-based treatment summaries used as public cross-checks. Verify the current NCCN version before clinical use.

Site-Specific Data Items (SSDI)

These are educational SSDI topic prompts, not a validated complete schema-specific SSDI list or coded values. Determine applicable items, collection requirements, definitions, codes and effective years from the official SSDI Manual and schema before abstracting.

NAACCR SSDI database ↗ · SEER SSDI resources ↗

AJCC / SEER EOD lung staging eligibility

This is a histology-range and primary-site screening aid based on published SEER EOD lung schemas, not a complete AJCC eligibility determination or stage assignment. Verify behavior, coding year, edition, and special histology schemas.

SEER EOD Lung V9 (2025+) · SEER EOD Lung 8th (2018–2024)

Localized sites and regional spread — SEER Summary Stage 2018

1 · Localized

Confined to lung or qualifying superficial bronchial disease; adjacent ipsilateral lobe can be localized under Summary Stage rules.

2 · Regional by extension

Examples include visceral pleural invasion, chest wall, mediastinum, trachea, or a separate tumor nodule in the same lobe. Exact documentation and applicable version govern.

3 · Regional nodes only

Ipsilateral bronchial, hilar, intrapulmonary, interlobar, lobar, segmental, subsegmental, mediastinal, subcarinal and paratracheal nodes (when qualifying).

4 · Extension and nodes

Both qualifying regional direct extension and regional lymph node involvement, without distant spread.

7 · Distant

Examples include supraclavicular nodes, contralateral or bilateral hilar/mediastinal nodes, and distant organ metastases. Summary Stage is not identical to AJCC TNM.

9 · Unknown

Extent cannot be determined from available documentation under applicable rules.

Regional nodal classification depends on the side of the primary. The selected lobe and histology alone do not establish stage. This is an educational overview, not an automatic staging determination.

SEER*RSA Lung Summary Stage 2018 definitions · Current Summary Stage Manual and revisions

Interactive IASLC lymph node stations — realistic thoracic anatomy

Click the numbered markers over the realistic thoracic illustration to select positive stations. Patient right is on the left in this anterior view. The background is an AI-generated educational illustration; marker placement is schematic and must not be used to determine exact IASLC station boundaries. Station numbers are anatomical identifiers, not EOD Regional Nodes codes.

RIGHT LUNG LEFT LUNG 1R: Low cervical / supraclavicular1R 1L: Low cervical / supraclavicular1L 2R: Upper paratracheal2R 2L: Upper paratracheal2L 3A: Prevascular3A 3P: Retrotracheal3P 4R: Lower paratracheal4R 4L: Lower paratracheal4L 5: Subaortic / aortopulmonary window5 6: Para-aortic6 7: Subcarinal7 8R: Paraesophageal8R 8L: Paraesophageal8L 9R: Pulmonary ligament9R 9L: Pulmonary ligament9L 10R: Hilar10R 10L: Hilar10L 11R: Interlobar11R 11L: Interlobar11L 12R: Lobar12R 12L: Lobar12L 13R: Segmental13R 13L: Segmental13L 14R: Subsegmental14R 14L: Subsegmental14L

Suggested AJCC N category from selected positive stations

N CATEGORY ASSESSMENT

Click any lymph node station to mark it positive.

POSITIVE STATIONS & RATIONALE

SEER SUMMARY STAGE CONTEXT

EDUCATIONAL INTERPRETATION

One-click selection: Every station you click is automatically positive. Click again to remove it. No additional status entry is needed.

● Red: selected (presumed positive)● Blue: not selected (status unknown)

Visual reference only: the background illustration is not a validated IASLC map. Use the official IASLC definitions to resolve station boundaries and staging questions.

No stations selected.

Note: Station 3 is designated 3A (prevascular) and 3P (retrotracheal), not 3R/3L. Station 1 nodes are AJCC N3 but distant under SEER Summary Stage for lung. Mediastinal stations 2–9 require attention to laterality and anatomical boundaries. A station designation alone does not establish pathologic nodal involvement or stage.

IASLC · SEER EOD Regional Nodes (Lung) · SEER Summary Stage Manual

Regional lymph nodes identified by code — Lung EOD Regional Nodes

NAACCR item #774 · SEER EOD Regional Nodes, Lung schema. These are three-digit EOD codes, not AJCC N categories, ICD-O codes, or one-digit Summary Stage codes. The descriptions below are for educational lookup; check the applicable schema version for the diagnosis year.

EOD codeAnatomical nodes / statusSS2018 mapping
000No regional lymph node involvementNone
300Ipsilateral hilar / bronchial: hilar (bronchopulmonary), peribronchial, intrapulmonary, interlobar, lobar, segmental and subsegmental nodes; typically stations 10–14Regional nodes
400Ipsilateral mediastinal: carinal/tracheobronchial, subcarinal (station 7), paratracheal, pretracheal, paraesophageal, pulmonary ligament, and other qualifying mediastinal nodes; includes mediastinal NOS as defined in schemaRegional nodes
600Ipsilateral or contralateral: low cervical, scalene, supraclavicular, sternal-notch nodesDistant
700Contralateral or bilateral: qualifying hilar, bronchial or mediastinal nodes (review schema-specific details)Distant
800Regional lymph node(s), NOS / lymph node(s), NOSRegional nodes
999Unknown / cannot assess / not documentedUnknown
EOD and Summary Stage use different code systems.

EOD Regional Nodes codes such as 400, 600, and 700 are three-digit EOD values and should not be read as Summary Stage codes 4, 6, or 7.

For lung, some nodal findings that AJCC categorizes as N3 may map to Summary Stage 7 (distant). The AJCC N category and SEER Summary Stage answer different staging questions and should be interpreted separately.

SEER Summary Stage 2018 — Complete Code Reference

0
In situNoninvasive disease confined to the epithelium.
1
Localized onlyDisease confined to the lung/primary organ without regional extension, regional nodes, or distant spread.
2
Regional — direct extension onlyRegional spread by direct extension with no regional lymph node involvement.
3
Regional — lymph nodes onlyRegional lymph node involvement without regional direct extension.
4
Regional — direct extension + lymph nodesBoth regional direct extension and regional lymph node involvement are present.
7
Distant site(s) / node(s)Distant metastasis and/or distant lymph node involvement.
8
Benign / borderlineValid Summary Stage 2018 code for applicable schemas; generally not used for a malignant lung primary.
9
UnknownInsufficient information to determine whether disease is localized, regional, or distant.

AJCC staging

Lung chapter / staging framework: exact AJCC version and schema must be checked against diagnosis year and applicable eligibility rules. This MVP does not automatically assign stage.

COMMON METASTATIC SITES — LUNG

Lung cancer can spread to many organs. The following are among the main distant metastatic sites identified by NCI.

COMMON

Brain

Frequent distant site; document confirmed brain involvement in Mets at Dx and staging fields.

COMMON

Bone

Common hematogenous site of spread.

COMMON

Liver

Common distant organ involvement.

COMMON

Adrenal gland

Classic distant metastatic site for lung primaries.

COMMON

Other lung

Contralateral pulmonary involvement may represent distant disease depending on the documented pattern and staging rules.

Registrar reminder: A common metastatic pattern is an educational clue only. Code M category, EOD Mets, Summary Stage, and Mets at Dx from documented disease and the current schema.

Sources

All external source links used throughout J'Onco Mentor are collected here for convenient review.

SEER ICD-O-3 Resourceshttps://seer.cancer.gov/icd-o-3/ SEER Solid Tumor Ruleshttps://seer.cancer.gov/tools/solidtumor/ SEER Combined Solid Tumor Rules PDFhttps://seer.cancer.gov/tools/solidtumor/current/STM_Combined.pdf SEER*RSA Staginghttps://staging.seer.cancer.gov/ IASLC AJCC Version 9 Lung Changeshttps://www.iaslc.org/file/10870/download?token=ZdsZFnAS IASLC Version 9 Lung TNM Stage Groupshttps://www.iaslc.org/file/10871/download?token=DmNIDkWP SEER 2027 Appendix C: Lung Surgery Codeshttps://seer.cancer.gov/manuals/2026/AppendixC/Surgery_Codes_Lung_2026.pdf NCCN Clinical Practice Guidelineshttps://www.nccn.org/guidelines/category_1 NAACCR SSDI Databasehttps://apps.naaccr.org/ssdi/list/ seer.cancer.govhttps://seer.cancer.gov/ssdi/ SEER*RSA Staginghttps://staging.seer.cancer.gov/eod_public/schema/3.3/lung_v9_2025/ SEER*RSA Staginghttps://staging.seer.cancer.gov/eod_public/schema/3.3/lung/ SEER*RSA Staginghttps://staging.seer.cancer.gov/eod_public/input/2.0/lung/ss2018/ SEER Summary Stage Manualhttps://seer.cancer.gov/tools/ssm/ iaslc.orghttps://www.iaslc.org/ SEER*RSA: Lung EOD Regional Nodeshttps://staging.seer.cancer.gov/eod_public/input/3.2/lung/eod_regional_nodes/ SEER Training: Lung Nodal Stationshttps://training.seer.cancer.gov/lung/staging/eod-regional-nodes.html SEER*RSA: Pleural Summary Stage Referencehttps://staging.seer.cancer.gov/eod_public/input/3.2/heart_mediastinum_pleura/ss2018/ SEER Training: ICD-O and ICDhttps://training.seer.cancer.gov/coding-primary/icdo-and-icd.html SEER Training: Lung Histologieshttps://training.seer.cancer.gov/lung/lung-histologies.html

Reference-checked seed content, not a substitute for current diagnosis-year-specific manuals. Biomarkers and treatment categories are illustrative and require separate clinical review before production use.

\n\n